Impetigo is a common infection of the superficial layers of the epidermis that is highly contagious and most commonly caused by gram-positive bacteria. It most commonly presents as erythematous plaques with a yellow crust and may be itchy or painful. The lesions are highly contagious and spread easily.
Impetigo is a disease of children who reside in hot humid climates. The infection may be bullous or nonbullous. The infection typically affects the face but can also occur in any other part of the body that has an abrasion, laceration, insect bite or other trauma.
Impetigo accounts for approximately 10% of skin complaints in the pediatric population. When considering all age ranges, the incidence is the same in males and females. In adults, men are more commonly affected. It is most prevalent in children aged 2-5 years old but can occur at any age. The peak incidence is during summer and fall. Bullous impetigo is more common in infants. Children younger than two account for 90% of cases of bullous impetigo.
Nonbullous impetigo is most commonly caused by S aureus which is responsible for 80% of cases. Group A beta-hemolytic Strep (GABHS) accounts for 10% of cases and the causative agent is a combination of S. aureus and GABHS 10% of the time. Methicillin-resistant S aureus (MRSA) has become more prevalent, especially in hospitalized patients. Today, community-acquired MRSA is rapidly increasing. The condition is more common in populations living in close quarters, daycare centers and prisons.
Bullous impetigo is caused almost exclusively by S aureus. Sometimes a deep ulcerated infection may occur known as ecthyma, which is a complication of bullous impetigo.
Impetigo can be classified as either primary or secondary. Primary impetigo involves previously normal skin affected by direct bacterial invasion. Secondary impetigo involves infection forming at a previous skin wound site.
Any disturbance of the skin barrier leads to access to fibronectin receptors by GABHS and S aureus which require fibronectin for colonization. Trauma, cuts, insect bites, surgery, atopic dermatitis, burns, and varicella are common mechanisms of skin breakdown. Once a lesion is present, self-inoculation to other sites is very common. Malnutrition, immunosuppression, daycare attendance, overcrowding, diabetes, and poor hygiene make one more susceptible to impetigo.
Triggers that breakdown skin and increase susceptibility to impetigo include:
Nonbullous impetigo often starts as a vesicle or a pustule. Multiple vesicles often coalesce and rupture after which the purulent exudate forms the characteristic honey-colored crust. An erythematous base is also present. There are often multiple lesions on the face and extremities, especially in areas in which disruption of the skin barrier has occurred. The rapid spread and satellite lesion formation follow self-inoculation, often in areas with no apparent break in the skin barrier. Mild regional lymphadenopathy is a common associated finding. Systemic symptoms such as fever are typically absent in nonbullous impetigo.
Bullous impetigo begins with small vesicles that become flaccid bullae. The exfoliative toxin A produced by S. aureus causes loss of cell adhesion in the superficial epidermis. The bullae contain a clear or yellow fluid which eventually progresses to become purulent or dark. Surrounding erythema and edema are typically absent. Once the bullae rupture, an erythematous base with a rim of scale remains. Bullous impetigo does not form a honey-colored crust. Lesions most commonly form in the intertriginous regions and on the trunk and, unlike nonbullous impetigo, may occur in the buccal membranes. There are typically fewer lesions present than in non-bullous impetigo. Regional lymphadenopathy is absent. Systemic symptoms, such as fever, are more common than in nonbullous impetigo.
Ecthyma is a deep tissue form of impetigo. Ulcerative lesions penetrate through the epidermis and deep into the dermis. These ulcers appear as “punched out” lesions with violaceous margins. The crusts can be honey-colored or brown-black. The lesions may be purulent.
History and physical exam are essential to the diagnosis of impetigo. Bacterial cultures can be used for confirmation of diagnosis and should be obtained if methicillin-resistant staph aureus (MRSA) is suspected or if an impetigo outbreak is present. A skin biopsy may be considered if the case is refractory.
The anti-streptolysin O (ASO) response is weak from impetigo alone. Therefore, serologic testing for streptococcal antibodies is not indicated for the diagnosis of impetigo. However, it may be useful if post-streptococcal glomerulonephritis is suspected in a patient with a recent impetigo outbreak.
Human immunodeficiency virus (HIV) testing should be considered when a previously healthy adult develops bullous impetigo.
Topical antibiotics alone or in conjunction with systemic antibiotics are used to treat impetigo. Antibiotic coverage should cover both S aureus and S pyogenes (i.e. GABHS). While untreated impetigo is often self-limiting, antibiotics decrease the duration of illness and spread of lesions. In addition, antibiotic treatment decreases the chances of complications involving kidneys, joints, bones, and lungs, as well as acute rheumatic fever.
For localized, uncomplicated, non-bullous impetigo, topical therapy alone is the treatment of choice. The crust should be removed with soap and water before the application of topical antibiotic therapy. Mupirocin, retapamulin, and fusidic acid are the treatments of choice.
Systemic antibiotics should be prescribed for all cases of bullous impetigo and cases of non-bullous impetigo with more than five lesions, deep tissue involvement, systemic signs of infection, lymphadenopathy or lesions in the oral cavity. Beta-lactamase-resistant antibiotics such as cephalosporins, amoxicillin-clavulanate, dicloxacillin are the treatment of choice. Cephalexin is commonly used. If culture confirms an infection solely caused by streptococci, oral penicillin is the preferred therapy.
In areas of high prevalence of MRSA or if cultures are positive for MRSA, clindamycin or doxycycline are the preferred treatments. Trimethoprim-sulfamethoxazole is effective against MRSA, but should only be used if group A streptococci are not the causative agent, or in addition to an anti-streptococcal antibiotic.
Children with impetigo should maintain good personal hygiene and avoid other children during the active outbreak. It is important to wash hands, linens, clothes and affected areas that may have come into contact with infected fluids. Sores can be covered with a bandage to help prevent spread by contact. If impetigo is recurrent, evaluation for carriage of the causative bacteria should be performed. The nose is a common reservoir and carriers can be treated with mupirocin (Bactroban Nasal) applied in the nostrils.
Without treatment, the infection heals in 14-21 days. About 20% of cases resolve spontaneously. Scarring is rare but some patients may develop pigmentation changes. Some patients may develop ecthyma. With treatment, cure occurs within 10 days. Neonates may develop meningitis. A rare complication is acute post streptococcal glomerulonephritis, whic occurs 2-3 weeks after the skin infection.
While most patients do improve with therapy, a few patients may develop renal failure. This is more likely if the infection is due to streptococcus. The renal dysfunction appears 7-14 days after the infection. The transient hematuria and proteinuria may last a few weeks or months. Other complications include septic arthritis, scarlet fever, sepsis, and staphylococcal scalded skin syndrome.
Approximately 5% of patients with impetigo will develop an associated glomerulonephritis. There is inconclusive evidence about whether or not antibiotics help reduce the incidence of poststreptococcal glomerulonephritis. Poststreptococcal glomerulonephritis typically occurs one to two weeks after a streptococcal infection. Patients may experience fever, hypertension, edema and hematuria.
Impetigo is usually managed by an interprofessional team that consists of a nurse practitioner, primary care provider, pediatrician, and a dermatologist. Topical antibiotics alone or in conjunction with systemic antibiotics are used to treat impetigo. Antibiotic coverage should cover both S aureus and S pyogenes (i.e. GABHS). While untreated impetigo is often self-limiting, antibiotics decrease the duration of illness and spread of lesions. In addition, antibiotic treatment decreases the chances of complications involving kidneys, joints, bones, and lungs, as well as acute rheumatic fever.
The infectious disease should educate the patient to refrain from touching the skin lesions and the importance of handwashing. Because the infection is contagious, the school nurse should recommend that the child not return to daycare os school for at least 24-48 hours after starting antibiotic therapy.
In areas of a high prevalence of MRSA or if cultures are positive for MRSA, clindamycin or doxycycline are the preferred treatments. Trimethoprim-sulfamethoxazole is effective against MRSA, but should only be used if group A streptococci are not the causative agent, or in addition to an anti-streptococcal antibiotic.
Clinicians should educate the caregivers that children with impetigo should maintain good personal hygiene and avoid other children during the active outbreak. It is important to wash hands, linens, clothes and affected areas that may have come into contact with infected fluids. Sores can be covered with a bandage to help prevent spread by contact. If impetigo is recurrent, evaluation for the carriage of the causative bacteria should be performed. The nose is a common reservoir and carriers can be treated with mupirocin (Bactroban Nasal) applied in the nostrils.
|||May PJ,Tong SYC,Steer AC,Currie BJ,Andrews RM,Carapetis JR,Bowen AC, Treatment, prevention and public health management of impetigo, scabies, crusted scabies and fungal skin infections in endemic populations: a systematic review. Tropical medicine [PubMed PMID: 30582783]|
|||Leung TN,Hon KL,Leung AK, Group A Streptococcus disease in Hong Kong children: an overview. Hong Kong medical journal = Xianggang yi xue za zhi. 2018 Dec; [PubMed PMID: 30416105]|
|||Clebak KT,Malone MA, Skin Infections. Primary care. 2018 Sep; [PubMed PMID: 30115333]|
|||Breyre A,Frazee BW, Skin and Soft Tissue Infections in the Emergency Department. Emergency medicine clinics of North America. 2018 Nov; [PubMed PMID: 30297001]|
|||Sahu JK,Mishra AK, Ozenoxacin: a novel drug discovery for the treatment of impetigo. Current drug discovery technologies. 2018 May 2; [PubMed PMID: 29732990]|
|||Castro MCR,Ramos-E-Silva M, Cutaneous infections in the mature patient. Clinics in dermatology. 2018 Mar - Apr; [PubMed PMID: 29566923]|
|||Dayrit JF,Bintanjoyo L,Andersen LK,Davis MDP, Impact of climate change on dermatological conditions related to flooding: update from the International Society of Dermatology Climate Change Committee. International journal of dermatology. 2018 Aug; [PubMed PMID: 29377078]|
|||Loadsman MEN,Verheij TJM,van der Velden AW, Impetigo incidence and treatment: a retrospective study of Dutch routine primary care data. Family practice. 2018 Oct 19; [PubMed PMID: 30346521]|
|||Smith DRM,Dolk FCK,Pouwels KB,Christie M,Robotham JV,Smieszek T, Defining the appropriateness and inappropriateness of antibiotic prescribing in primary care. The Journal of antimicrobial chemotherapy. 2018 Feb 1; [PubMed PMID: 29490061]|
|||Rush J,Dinulos JG, Childhood skin and soft tissue infections: new discoveries and guidelines regarding the management of bacterial soft tissue infections, molluscum contagiosum, and warts. Current opinion in pediatrics. 2016 Apr; [PubMed PMID: 26900921]|
|||Rosen T,Albareda N,Rosenberg N,Alonso FG,Roth S,Zsolt I,Hebert AA, Efficacy and Safety of Ozenoxacin Cream for Treatment of Adult and Pediatric Patients With Impetigo: A Randomized Clinical Trial. JAMA dermatology. 2018 Jul 1; [PubMed PMID: 29898217]|
|||Nasr SH,Fidler ME,Valeri AM,Cornell LD,Sethi S,Zoller A,Stokes MB,Markowitz GS,D'Agati VD, Postinfectious glomerulonephritis in the elderly. Journal of the American Society of Nephrology : JASN. 2011 Jan; [PubMed PMID: 21051737]|